AlphaCrest Capital Management’s Intellia Therapeutics NTLA Stock Holding History

AlphaCrest Capital Management’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,877	Closed	-$222K	–	1359
2021 Q4	$222K	Buy	+1,877	New	+$235K	0.01%	1316
2021 Q1	–	Sell	-9,200	Closed	-$500K	–	1268
2020 Q4	$500K	Sell	9,200 -36,100	-80%	-$1.31M	0.04%	646
2020 Q3	$901K	Buy	+45,300	New	+$945K	0.1%	296
2019 Q3	–	Sell	-15,500	Closed	-$254K	–	1304
2019 Q2	$254K	Buy	15,500 +5,400	+53%	+$84.9K	0.02%	911
2019 Q1	$173K	Buy	+10,100	New	+$151K	0.03%	786

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

AlphaCrest Capital Management's NTLA Position: Q1 2022 in Review

AlphaCrest Capital Management sold out of Intellia Therapeutics (NTLA) in Q1 2022, closing a stake of 1,877 shares — an estimated $222K sold.

AlphaCrest Capital Management first reported a position in NTLA in Q1 2019 and held it in 5 quarters. The position peaked at $901K in Q3 2020. 348 funds tracked by Wall St. Rank hold NTLA as of Q1 2022.

AlphaCrest Capital Management reported no remaining Intellia Therapeutics position as of Q1 2022 after selling out during the quarter.
AlphaCrest Capital Management sold 1,877 Intellia Therapeutics shares in Q1 2022, an estimated $222K.
AlphaCrest Capital Management first reported a position in Intellia Therapeutics in Q1 2019 and held it in 5 quarters.
AlphaCrest Capital Management's Intellia Therapeutics position peaked at $901K in Q3 2020.
348 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2022.

Based on AlphaCrest Capital Management's 13F filing for Q1 2022, filed 12 May 2022.